Openbookopenbook
Equity
Volitionrx Ltd(VNRX)
USD --+0.00%
Reward63Moderate
Risk78High
📊75%Data
Revenue growing 32% YoY
VNRX
+0.0 · +0.00%
USD · NYSE MKT
Volitionrx Ltd | Healthcare
Profitless Growth
Market Cap:28.88M
ℹ️
Reward Rating
63
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
78
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on VNRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.20.

What is Volitionrx Ltd?

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.

VNRX · Verdict

Solid reward · high risk

VNRX stands out on growth and valuation, but watch the balance sheet signal.

Based on 88% data coverage

VNRX · Verdict

What’s working & what to watch

Strengths 2

  • Growth81/100

    Rev +139.3% CAGR · earnings +0.2%

  • Valuation78/100

    P/E 10.5×

Watchouts 4

  • Balance sheet6/100

    Current ratio 0.52

  • Cash flow29/100

    -2146% free-cash-flow margin

  • Profitability32/100

    -2186% net margin · -730% ROE

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Volitionrx Ltd?

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. Q Vet, a cancer screening test for dogs and other animals; Nu. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 28.88M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (63)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap28.88M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.94
52 Week Low0.17
Last AnnualDecember
IPO Date4/25/2007
IncorporatedUSA
Shares Outstanding136M
No. of Employees75
IndustryMedical Devices
ExchangeNYSE MKT
Beta1.302
CurrencyUSD
Websitevolition.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.